Fresenius SE





Investor News 2008

23.12.2008Phase II study shows trifunctional antibody Removab® (catumaxomab) well tolerated in treatment of gastric cancer
PDF Text as PDF-File
22.12.2008HELIOS awarded two hospital privatization projects in Germany
PDF Text as PDF-File
02.12.2008Capital Market Day: Fresenius Helios and Fresenius Vamed poised for continued growth
PDF Text as PDF-File
04.11.2008Q1-3/2008: Continued strong growth − Sales outlook raised
PDF Text as PDF-File
30.09.2008Syndicated Credit Facilities for APP Pharmaceuticals acquisition financing increased by US$ 500 million due to strong demand
PDF Text as PDF-File
10.09.2008Fresenius closes APP acquisition
PDF Text as PDF-File
02.09.2008Fresenius and APP Pharmaceuticals Announce Clearance of APP Acquisition by U.S. Federal Trade Commission
PDF Text as PDF-File
28.08.2008Moody’s confirms Fresenius SE’s Ba1 rating
PDF Text as PDF-File
12.08.2008Fresenius SE successfully completes capital increase
PDF Text as PDF-File
11.08.2008Acquisition of Dabur Pharma successfully closed
PDF Text as PDF-File
11.08.2008Substantial oversubscription in first phase of syndication of US$ 2,400 million Senior Secured Credit Facilities
PDF Text as PDF-File
11.08.2008Fresenius resolves on capital increase
PDF Text as PDF-File
30.07.2008First half 2008: Strong financial results
PDF Text as PDF-File
17.07.2008Strong financial results in the first half of 2008 (preliminary figures)
PDF Text as PDF-File
17.07.2008Issuance of mandatory exchangeable bonds, exchangeable into ordinary shares of Fresenius Medical Care AG & Co. KGaA
PDF Text as PDF-File
17.07.2008Fresenius SE successfully executes offering of € 554 million mandatory exchangeable bonds, exchangeable into ordinary shares of Fresenius Medical Care
PDF Text as PDF-File
07.07.2008Fresenius Kabi to acquire APP Pharmaceuticals – entry into North American I.V. generics market provides excellent growth opportunities
PDF Text as PDF-File
20.05.2008Moody's upgrades rating of Fresenius SE to Ba1
PDF Text as PDF-File
30.04.2008Q1 2008: Successful start into 2008
(for additional tables please see pdf-file)
PDF Text as PDF-File
20.04.2008Fresenius Kabi strengthens its position in i.v. drugs by acquiring Dabur Pharma, a leading manufacturer of oncology generics
PDF Text as PDF-File
20.02.2008Fresenius achieves record financial results in 2007
Positive outlook for 2008
(for additional tables please see pdf-file)
PDF Text as PDF-File
20.02.2008Consolidated Statement of Income, Balance Sheet, Cash Flow 2007 - US-GAAP as PDF